(PRTG) – Hot Corp. News
-
Biohaven Pharma (BHVN) Phase 3 Clinical Trial Evaluating Troriluzole for Spinocerebellar Ataxia Did Not Reach Statistical Significance
-
Biohaven Pharma (BHVN) and Pfizer (PFE) announce strategic collaboration for the global commercialization of NURTEC ODT outside the United States
Back to PRTG Stock Lookup
